

Chi-Huey Wong (Ed.)

Carbohydrate-based Drug Discovery

Volume 1



**WILEY-
VCH**

WILEY-VCH GmbH & Co. KGaA

Contents

Volume 1

Preface XXV

List of Contributors XXVII

- 1 Synthetic Methodologies 1**
Chikako Saotome and Osamu Kanie
- 1.1 Introduction 1
- 1.2 Tactical Analysis for Overall Synthetic Efficiency 1
- 1.3 Methodological Improvements 2
- 1.3.1 Chemistry 3
- 1.3.2 Protecting Group Manipulations 4
- 1.3.3 Modulation of the Reactivity of Glycosyl Donors 6
- 1.3.4 Block Synthesis 8
- 1.4 Accessibility 11
- 1.4.1 Solution-based Chemistry 11
- 1.4.2 One-Pot Glycosylation 13
- 1.4.3 Solid-Phase Chemistry 16
- 1.4.3.1 Fundamentals of Solid-Phase Oligosaccharide Synthesis 16
- 1.4.3.2 The Support 16
- 1.4.3.3 Linkers to the Support 20
- 1.4.3.4 Protecting Groups used in Solid-Phase Oligosaccharide Synthesis 20
- 1.4.3.5 Solid-Phase Oligosaccharide Synthesis 20
- 1.4.3.6 Monitoring of Reaction Progress 26
- 1.4.4 Automation 29
- 1.5 Concluding Remarks 32
- 1.6 References 33
- 2 Complex Carbohydrate Synthesis 37**
Makoto Kiso, Hideharu Ishida, and Hiromune Ando
- 2.1 Introduction 37
- 2.2 Synthetic Gangliosides 38
- 2.2.1 Gangliosides GM4 and GM3, and their Analogues and Derivatives 38

2.2.2	Sialylparagloboside (SPG) Analogues and Derivatives	40
2.2.3	Selectin Ligands	43
2.2.3.1	Sialyl Lewis x	44
2.2.3.2	Novel 6-Sulfo sLe ^x Variants	45
2.2.4	Siglec ligands	46
2.2.4.1	Chol-1 (α -Series) Gangliosides	47
2.2.4.2	Novel Sulfated Gangliosides	50
2.3	Toxin Receptor	50
2.4	Summary and Perspectives	52
2.5	References	52
3	The Chemistry of Sialic Acid	55
	<i>Geert-Jan Boons and Alexei V. Demchenko</i>	
3.1	Introduction	55
3.2	Chemical and Enzymatic Synthesis of Sialic Acids	56
3.3	Chemical Glycosidation of Sialic Acids	59
3.3.1	Direct Chemical Sialylations	60
3.3.1.1	2-Chloro Derivatives as Glycosyl Donors	61
3.3.1.2	2-Thio Derivatives as Glycosyl Donors	62
3.3.1.3	2-Xanthates as Glycosyl Donors	69
3.3.1.3	2-Phosphites as Glycosyl Donors	71
3.3.1.4	Miscellaneous Direct Chemical Methods	71
3.3.2	Indirect Chemical Methods with the Use of a Participating Auxiliary at C-3	73
3.3.2.1	3-Bromo- and other 3-O-Auxiliaries	73
3.3.2.2	3-Thio and 3-Seleno Auxiliaries	74
3.3.3	Synthesis of (2→8)-Linked Sialosides	77
3.4	Enzymatic Glycosidations of Sialic Acids	83
3.4.1	Sialyltransferases	84
3.4.1.1	Metabolic Engineering of the Sialic Acid Biosynthetic Pathway	90
3.4.2	Sialidases	90
3.5	Synthesis of C- and S-Glycosides of Sialic Acid	91
3.6	Modifications at N-5	94
3.7	References	95
4	Solid-Phase Oligosaccharide Synthesis	103
	<i>Peter H. Seeberger</i>	
4.1	Introduction	103
4.2	Pioneering Efforts in Solid-Phase Oligosaccharide Synthesis	104
4.3	Synthetic Strategies	105
4.3.1	Immobilization of the Glycosyl Acceptor	106
4.3.2	Immobilization of the Glycosyl Donor	106
4.3.3	Bi-directional Strategy	107
4.4	Support Materials	107
4.4.1	Insoluble Supports	107

4.4.2	Soluble Supports	108
4.5	Linkers	108
4.5.1	Silyl Ethers	108
4.5.2	Acid- and Base-Labile Linkers	109
4.5.3	Thioglycoside Linkers	110
4.5.4	Linkers Cleaved by Oxidation	110
4.5.5	Photocleavable Linkers	111
4.5.6	Linkers Cleaved by Olefin Metathesis	111
4.6	Synthesis of Oligosaccharides on Solid Support by Use of Different Glycosylating Agents	112
4.6.1	1,2-Anhydrosugars – The Glycal Assembly Approach	112
4.6.2	Glycosyl Sulfoxides	113
4.6.3	Glycosyl Trichloroacetimidates	114
4.6.4	Thioglycosides	115
4.6.5	Glycosyl Fluorides	118
4.6.6	<i>n</i> -Pentenyl Glycosides	118
4.6.7	Glycosyl Phosphates	118
4.7	Automated Solid-Phase Oligosaccharide Synthesis	118
4.7.1	Fundamental Considerations	119
4.7.2	Automated Synthesis with Glycosyl Trichloroacetimidates	121
4.7.3	Automated Synthesis with Glycosyl Phosphates	121
4.7.4	Automated Oligosaccharide Synthesis by Use of Different Glycosylating Agents	121
4.7.5	“Cap-Tags” to Suppress Deletion Sequences	123
4.7.6	Current State of the Art of Automated Synthesis	123
4.8	Conclusion and Outlook	124
4.9	References	125
5	Solution and Polymer-Supported Synthesis of Carbohydrates	129
	<i>Shin-Ichiro Nishimura</i>	
5.1	Introduction	129
5.2	Mimicking Glycoprotein Biosynthetic Systems	130
5.3	References	136
6	Enzymatic Synthesis of Oligosaccharides	
	<i>Jianbo Zhang, Jun Shao, Prezemk Kowal, and Peng George Wang</i>	
6.1	Introduction	137
6.2	Sugar Nucleotide Biosynthetic Pathways	140
6.2.1	Basic Principle	140
6.2.2	Regeneration Systems for nine Common Sugar Nucleotides	142
6.2.2.1	Regeneration Systems for UDP-Gal, UDP-Glc, UDP-GlcA and UDP-Xyl	142
6.2.2.2	Regeneration Systems for UDP-GlcNAc and UDP-GalNAc	144
6.2.2.3	Regeneration Systems for GDP-Man and GDP-Fuc	147
6.2.2.4	CMP-Neu5Ac Regeneration	149

6.2.3	Novel Energy Source in Sugar Nucleotide Regeneration	150
6.3	Enzymatic Oligosaccharide Synthesis Processes	151
6.3.1	Cell-Free Oligosaccharide Synthesis	151
6.3.1.1	Immobilized Glycosyltransferases and Water-Soluble Glycopolymer	152
6.3.1.2	“Superbeads”	154
6.3.2	Large-Scale Syntheses of Oligosaccharides with Whole Cells	156
6.3.2.1	Kyowa Hakko’s Technology	157
6.3.2.2	Wang’s “Superbug”	157
6.3.2.3	Other Whole Cell-Based Technologies	161
6.4	Future Directions	162
6.5	References	162
7	Glycopeptides and Glycoproteins: Synthetic Chemistry and Biology	169
	<i>Oliver Seitz</i>	
7.1	Introduction	169
7.2	The Glycosidic Linkage	169
7.3	The Challenges of Glycopeptide Synthesis	171
7.4	Synthesis of Preformed Glycosyl Amino Acids	173
7.4.1	N-Glycosides	173
7.4.2	O-Glycosides	176
7.4.2.1	O-Glycosyl Amino Acids bearing Mono- or Disaccharides	176
7.4.2.2	O-Glycosyl Amino Acids bearing Complex Carbohydrates	179
7.5	Synthesis of Glycopeptides	181
7.5.1	N-Glycopeptide Synthesis in Solution	181
7.5.2	O-Glycopeptide Synthesis in Solution	185
7.5.3	Solid-Phase Synthesis of N-Glycopeptides	188
7.5.4	Solid-Phase Synthesis of O-Glycopeptides	192
7.6	Biological and Biophysical Studies	200
7.6.1	Conformations of Glycopeptides	200
7.6.2	Glycopeptides as Substrates of Enzymes and Receptors	203
7.6.3	Glycopeptides and Cancer Immunotherapy	204
7.6.4	Glycopeptides and T Cell Recognition	206
7.7	Summary and Outlook	208
7.8	References	209
8	Synthesis of Complex Carbohydrates: Everninomicin 13,384-1	215
	<i>K. C. Nicolaou, Helen J. Mitchell, and Scott A. Snyder</i>	
8.1	Introduction	215
8.2	Retrosynthetic Analysis and Strategy	218
8.2.1	Overview of Synthetic Strategies and Methodologies	218
8.2.2	Retrosynthetic Analysis: Overall Approach	222
8.3	Total Synthesis of Everninomicin 13,384-1 (1)	223
8.3.1	Approaches Towards the A ₁ B(A)C Fragment	223
8.3.1.1	Initial Model Studies	223
8.3.1.2	Construction of the Building Blocks	225

8.3.1.3	Assembly and Completion of the A ₁ B(A)C Fragment	229
8.3.2	Construction of the FGHA ₂ Fragment	231
8.3.2.1	First Generation Approach to the FGHA ₂ Fragment	231
8.3.2.2	Second Generation Strategy Towards the FGHA ₂ Fragment	232
8.3.2.3	Assembly of the FGHA ₂ Fragment	235
8.3.3	Construction of the DE Disaccharide	241
8.3.3.1	Retrosynthetic Analysis and Construction of Building Blocks for the DE Fragment	241
8.3.3.2	Assembly of the DE Fragment	243
8.3.3.3	Test of Strategies	244
8.3.4	Assembly of the DEFGHA ₂ Fragment	245
8.3.5	Completion of the Total Synthesis of Everninomicin 13,384-1	247
8.4	Conclusion	249
8.5	References	250
9	Chemical Synthesis of Asparagine-Linked Glycoprotein Oligosaccharides: Recent Examples	253
	<i>Yukishige Ito and Ichiro Matsuo</i>	
9.1	Introduction	253
9.2	Synthesis of Asn-Linked Oligosaccharides: Basic Principles	257
9.3	Chemical Synthesis of Complex Oligosaccharides	261
9.3.1	Classical Examples	261
9.3.2	Trichloroacetimidate Approach to Complex-Type Glycan Chains	265
9.3.3	<i>n</i> -Pentenyl Glycosides as Glycosyl Donors	265
9.3.4	Glycal Approach to Complex Oligosaccharides	267
9.3.5	Intramolecular Aglycon Delivery Approach	269
9.3.6	New Protecting Group Strategy	273
9.3.7	Linear Synthesis of Branched Oligosaccharide	274
9.3.8	Chemoenzymatic Approach to Complex-type Glycans	275
9.4	References	278
10	Chemistry and Biochemistry of Asparagine-Linked Protein Glycosylation	281
	<i>Barbara Imperiali and Vincent W.-F. Tai</i>	
10.1	Protein Glycosylation	281
10.1.1	Introduction	281
10.1.2	Asparagine-Linked Glycosylation and Oligosaccharyl Transferase	281
10.2	Small-Molecule Probes of the Biochemistry of Oligosaccharyl Transferase	283
10.2.1	Photoaffinity and Affinity Labeling of Oligosaccharyl Transferase	284
10.2.2	Investigation of Peptide-Based Substrate Analogues as Inhibitors of Oligosaccharyl Transferase	287
10.2.2.1	Inhibitors of <i>N</i> -Linked Glycosylation and Glycoprotein Processing	287
10.2.2.2	Peptide-Based Analogues and Inhibitors	288
10.2.2.3	Interim Summary	292

10.2.3	Investigation of Carbohydrate-Based Substrate Analogues as Probes of Oligosaccharyl Transferase Function	292
10.2.3.1	Possible Mechanisms for Glycosyl Transfer	294
10.2.3.2	Probing of the Mechanism of Oligosaccharyl Transferase with Potential Inhibitors	296
10.2.3.3	Interim Summary	300
10.3	Conclusions	301
10.4	References	301
11	Conformational Analysis of C-Glycosides and Related Compounds: Programming Conformational Profiles of C- and O-Glycosides	305
	<i>Peter G. Goekjian, Alexander Wei, and Yoshito Kishi</i>	
11.1	Introduction	305
11.2	Stereoelectronic Effects and the <i>exo</i> -Anomeric Conformation	306
11.3	Conformational Analysis of C-Glycosides: C-Monoglycosides	309
11.4	1,4-Linked C-Disaccharides: the Importance of <i>syn</i> -Pentane Interactions	314
11.5	Prediction of Conformational Preference and Experimental Validation	318
11.6	Programming Oligosaccharide Conformation	322
11.7	Conformational Design of C-Trisaccharides based on a Human Blood Group Antigen	323
11.8	Conformational Design: Relationship to Biological Activity	330
11.8.1	C-Lactose vs. O-Lactose	331
11.8.2	Human Blood Group Trisaccharides	334
11.9	Concluding Remarks	336
11.10	Acknowledgements	337
11.11	References	337
12	Synthetic Lipid A Antagonists for Sepsis Treatment	341
	<i>William J. Christ, Lynn D. Hawkins, Michael D. Lewis, and Yoshito Kishi</i>	
12.1	Background	341
12.2	Hypothesis and Approach	342
12.2.1	Monosaccharide Antagonists: Lipid X Analogues	343
12.2.2	Disaccharide Antagonist of Lipid A: First Generation	344
12.2.3	Disaccharide Antagonist of Lipid A: Second Generation	348
12.3	Conclusion	351
12.4	Acknowledgement	353
12.5	References	353
13	Polysialic Acid Vaccines	357
	<i>Harold J. Jennings</i>	
13.1	Introduction	357
13.2	Group C Meningococcal Vaccines	358

- 13.2.1 Structure and Immunology of GCMP 358
- 13.2.2 Group C Conjugate Vaccines 360
- 13.3 Group B Meningococcal Vaccines 362
 - 13.3.1 Structure of GBMP 362
 - 13.3.2 Immunology of GBMP 362
 - 13.3.3 B Polysaccharide-Protein Conjugates 363
 - 13.3.4 Extended Helical Epitope of PSA 364
- 13.4 Chemically Modified Group B Meningococcal Vaccines 366
 - 13.4.1 *N*-Propionylated PSA Conjugate Vaccine 366
 - 13.4.2 Immunology of NPr PSA 368
 - 13.4.3 Protective Epitope mimicked by NPr PSA 370
 - 13.4.4 Safety Concerns 370
- 13.5 Cancer Vaccines 371
 - 13.5.1 PSA on Human Cells 371
 - 13.5.2 Potential of NPr PSA as a Cancer Vaccine 373
- 13.6 Acknowledgements 375
- 13.7 References 375

- 14 Synthetic Carbohydrate-Based Vaccines 381**
Stacy J. Keding and Samuel J. Danishefsky
 - 14.1 Introduction 381
 - 14.2 Cancer Vaccines 382
 - 14.2.1 Carrier Proteins 384
 - 14.2.2 Lipid Carriers 392
 - 14.2.3 T-Cell Epitopes 394
 - 14.2.4 Dendrimers 396
 - 14.3 Bacterial Polysaccharide Vaccines 397
 - 14.4 Synthetic Parasitic Polysaccharide Conjugate Vaccine 402
 - 14.5 Conclusions 403
 - 14.6 References 403

- 15 Chemistry, Biochemistry, and Pharmaceutical Potentials of Glycosaminoglycans and Related Saccharides 407**
Tasneem Islam and Robert J. Linhardt
 - 15.1 Introduction 407
 - 15.1.1 Biological Activities 408
 - 15.1.2 Heparin and Heparan Sulfate 409
 - 15.1.2.1 Structure and Properties 409
 - 15.1.2.2 Biosynthesis and Biological Functions 410
 - 15.1.2.3 Applications of Heparin and Heparan Sulfate 411
 - 15.2 Dermatan and Chondroitin Sulfates 417
 - 15.2.1 Structure and Biological Role 417
 - 15.2.2 Therapeutic Applications 418
 - 15.2.2.1 Dermatan Sulfate 418

15.2.2.2	Chondroitin Sulfates	419
15.3	Hyaluronan	419
15.3.1	Structure and Properties	419
15.3.2	Tissue Distribution and Biosynthesis	420
15.3.3	Functions and Applications	421
15.3.3.1	Medical Applications	422
15.3.3.2	Hyaluronic Acid Biomaterials	423
15.4	Keratan Sulfate	423
15.4.1	Structure and Distribution	423
15.4.2	Chemistry and Biosynthesis of Linkage Regions	424
15.4.2.1	Keratan Sulfate on Cartilage Proteoglycans	424
15.4.2.2	Keratan Sulfate on Corneal Proteoglycans	424
15.4.3	Biological Roles of Keratan Sulfate	425
15.4.3.1	Role of KS in Macular Corneal Dystrophy	425
15.5	Other Acidic Polysaccharides	425
15.5.1	Acharan Sulfate	425
15.5.2	Fucoidins	426
15.5.3	Carrageenans	427
15.5.4	Sulfated Chitins	427
15.5.5	Dextran Sulfate	427
15.5.6	Alginates	428
15.5.7	Fully Synthetic Sulfated Molecules	428
15.5.7.1	Polymers	428
15.5.7.2	Small Sulfonated Molecules	428
15.6	Pharmaceutical Potential and Challenges	430
15.6.1	GAG-Based Agents Are Heterogenous	431
15.6.2	GAG-Based Agents and Sulfonated Analogues Have Low Bioavailability	431
15.6.3	GAGs Have a Myriad of Biological Activities	432
15.6.4	Carbohydrate-Based Drugs Are Expensive and Difficult to Prepare	432
15.7	Conclusion	432
15.8	References	433
16	A New Generation of Antithrombotics Based on Synthetic Oligosaccharides	441
	<i>Maurice Petitou and Jean-Marc Herbert</i>	
16.1	Introduction	441
16.2	Heparin and Its Mechanism of Action as an Antithrombotic Agent	442
16.2.1	Heparin, a Complex Polysaccharide with Blood Anticoagulant Properties	442
16.2.2	Which Coagulation Factor must be Inhibited?	442
16.2.3	The Structure of Heparin in Relation to Antithrombin Activation	444
16.2.4	The Limitations of Heparin	445
16.3	Synthetic Pentasaccharides, Selective Factor Xa Inhibitors, are Antithrombotic Agents	446

16.3.1	New Synthetic Oligosaccharides Required in Order to Validate A Pharmacological Hypothesis	446
16.3.2	A Strategy for the Synthesis of an Active Pentasaccharide	446
16.3.3	A Strategy for the Synthesis of the First Pentasaccharide	448
16.3.4	Activation of Antithrombin: Structure/Activity Relationship	449
16.3.5	Clinical Trials Results	449
16.3.6	The Second Generation of Antithrombotic Pentasaccharides	451
16.4	Synthetic Thrombin-Inhibiting Oligosaccharides: The Next Generation?	452
16.4.1	First Approach: Oligomerization of a Disaccharide	452
16.4.2	Second Approach: Molecules Containing Two Identified Domains	453
16.4.3	Introduction of a Neutral Domain	454
16.5	The Mechanism of Antithrombin Activation by Synthetic Oligosaccharides	456
16.6	Conclusion and Perspectives	456
16.7	References	457

Volume 2

17	Sequencing of Oligosaccharides and Glycoproteins	461
	<i>Stuart M. Haslam, Kay-Hooi Khoo, and Anne Dell</i>	
17.1	Mass Spectrometry	462
17.1.1	EI-, FAB-, and MALDI-MS	462
17.1.2	ES, NanoES, and LC-MS	464
17.1.3	MS/MS and Mass Analyzers	465
17.2	MS-Based Sequencing Strategies	466
17.2.1	Chemical Derivatization	467
17.2.2	MS/MS Fragmentation Patterns	467
17.2.3	Permethylation and Sequence Assignment from Fragment Ions	468
17.3	Glycan Sequencing and Structural Determination – A Case Study	470
17.3.1	GC-MS Sugar Analysis	471
17.3.2	Glycan Derivatization	471
17.3.3	FAB-MS of the Deuteroreduced Permethylated HSP Sample	473
17.3.4	ES-MS/MS	473
17.3.5	Linkage Analysis	474
17.3.6	Chemical Hydrolysis	474
17.3.7	Exo-Glycosidase Digestion	474
17.4	Mammalian Glycomics	475
17.5	Some Special Case Strategies	477
17.6	References	481